ライフサイエンスコーパス: i.p.

1 i.p. Insl5 increased food intake in wild-type mice but n

2 BALB/c mice were sensitized to OVA (day 0) i.p. and challenged intranasal (12-15 d later) to induce

3 n vitro profile, contilisant (at 1 mg kg(-1) i.p.) also significantly improved lipopolysaccharide-ind

4 iet and low-dose streptozotocin (25mgkg(-1), i.p.) in rats.

5 nic exposure (7 or 21 days) to WIN 55,212-2 (i.p., 3.7 mg/kg), a potent cannabinoid agonist, on dendr

6 At 38 h posttreatment (80 mg/kg x 3, i.p.), CP9 led to selective disruption of Hsp90alpha/p23

7 Currently, 3 of 4 i.p./s.c.- and 2 of 4 p.o. secondary passage-inoculated

8 on (15 Gy), we injected small molecule 77427 i.p. approximately 1 hour after radiation then twice wee

9 tested our hypothesis by administering HUP-A i.p. or intrathecally to female Sprague-Dawley rats (200

10 Neutrophils were depleted using anti-Gr1 Ab (i.p. 0.5 mg/mouse/every 3 d).

11 of proinflammatory cytokines following acute i.p. challenge with LPS plus ATP in a manner that is pro

12 s reduced when C. difficile was administered i.p., suggesting that Nod1 directly recognizes C. diffic

13 Similarly, SB202190 administration (i.p.) abolished UBR2 up-regulation in the tibialis anter

14 After i.p. injection in mice, g-EAR showed gelation in the per

15 After i.p. injection of LPS, lower levels of TNFalpha, IL-6, a

16 After i.p. injection, percent phagocytosis of GPs by peritonea

17 g lymph nodes (dLNs) and the spleen 6h after i.p. immunization, as compared to after i.m. immunizatio

18 WT mice with N. menigitidis B-MC58 6 h after i.p. administration of Pn (100 microg/mouse) or buffer a

19 (18 m min(-1) ; 5 degrees grade), 1 h after i.p. administration of rapamycin (1.5 mg . kg(-1) ) or v

20 At 6 h after i.p. LPS injection, transgenic hSR-BI and hSR-BII mice d

21 mplete protection against organ injury after i.p. LPS.

22 term birth are rapidly induced in mice after i.p. injection of CpG or fetal DNA (300 mug/dam) on gest

23 Thirty minutes after i.p. injection of alcohol, mice received i.v. challenge

24 induce a CD4(+) T cell IL-17 response after i.p. immunization is associated with T cell priming, as

25 he in vivo PK experiments, 14i showed, after i.p. dosing, encouraging plasma PK profile and brain exp

26 teric lymph nodes (MLN) and the spleen after i.p. and s.c. immunization.

27 ro (in primary monocytes) and in vivo (after i.p. injection in the mouse).

28 We report that at 2 wk after i.p. or transtracheal delivery of 1 x 10(6) OVA-, but no

29 city and higher therapeutic efficacy against i.p. chemotherapy-resistant uterine serous carcinoma-der

30 In an OVA/Alum i.p.-sensitization mouse model, Amb-APE was intranasally

31 An i.p. injection of AVP to LXRbeta(-/-) mice revealed a pa

32 infusion of a Gd-based Zn(II) sensor and an i.p. bolus of glucose.

33 Diabetes was induced in Wistar rats by an i.p. injection of streptozotocin.

34 Two hours after CLP, an i.p. injection of 200 mug/kg of anti-rat NPCT antibody w

35 In contrast to an i.p. infectious model, in which IL-12p35, MHCII, and B c

36 hibition in MM tumor growth in both s.c. and i.p. models and the presence of a chemotherapeutic drug,

37 eficiency mice, and tumor growth in s.c. and i.p. models of MM was followed.

38 litaxel was administered i.v. at 50 mg/m and i.p. at 20 mg/m on days 1 and 8.

39 litaxel was administered i.v. at 50 mg/m and i.p. at 20 mg/m on days 1 and 8.

40 ctive dose) of MARV/Ang-MA in SCID mice, and i.p. infection at a dose of 1,000x LD50 resulted in deat

41 beginning at 3 days p.i. from both i.n.- and i.p.-challenged animals.

42 1R was sufficient to normalize both oral and i.p. glucose tolerance in Glp1r-/- mice.

43 m from Pneumocystis-infected mice as well as i.p. injection of Pneumocystis into uninfected IFrag(-/-

44 armacological PI3K-gamma inhibitor AS252424 (i.p. 10 mg/kg daily) or genetically using Pi3k-gamma(-/-

45 Treatment of mice with 5-azacytidine (i.p.) resulted in a significant dose-dependent increase

46 d no drug tolerance following repeated bolus i.p. or chronic intrathecal HUP-A dosing.

47 Most importantly, both i.p. and intranasal immunization with these NPs offered

48 when challenged with S. aureus or E. coli by i.p. injection.

49 alleviated fetal demise in utero elicited by i.p. LPS administration in late gestation.

50 cute necrotizing pancreatitis was induced by i.p. administration of cerulein or by intraductal admini

51 ce in which acute lung injury was induced by i.p. administration of LPS, we observed a rapid decrease

52 pH unit changes in vivo in tumors induced by i.p. injection of glucose.

53 odel of mild systemic endoxotemia induced by i.p. injection of lipopolysaccharide, we report that JAM

54 PION-actin or SPION-nestin at 4 mg Fe/kg) by i.p. injection to C57black6 mice that had experienced BC

55 at1-knockout (KO) and wild-type (WT) mice by i.p. injection of class II-disparate bm12 splenocytes.

56 ice were administered with METH or saline by i.p. injections for 5 days with an escalating dose regim

57 /c mice were treated with monoclonal anti-C5 i.p. on day 3 or 6 after intragastric inoculation and mo

58 umor efficacy in an ES-2-luc, ovarian cancer i.p. xenograft model.

59 competent BALB/c and C57BL/6 mice challenged i.p. with 2,000x LD50 of MARV/Ang-MA.

60 Chronic i.p. treatment of the triple transgenic (APPsw/PS1M146V/

61 e trained to discriminate 10.0 mg/kg CR4056 (i.p.) from vehicle in a two-lever food-reinforced drug d

62 Furthermore, daily i.p. injection of SR3306 (7 days) prevented the increase

63 In WT mice treated with 2 wk of daily i.p. injections of either 7,8 DHF or deoxygedunin (5 mg/

64 Newborn rat pups received daily i.p. injections of a human-relevant tapering dose of dex

65 eptide (0.3, 1, and 3 muM, given twice daily i.p. for 4 days).

66 Mice were simultaneously treated with daily i.p. injections of As(2)O(3).

67 Low-dose CP55,940 (0.3 mg/kg daily, i.p. ) suppressed paclitaxel-induced allodynia in WT and

68 (1) receptors since AM281 (0.33 mg/kg daily, i.p.) blocked the effect of URB597.

69 High-dose CP55,940 (10 mg/kg daily, i.p.) produced catalepsy in WT mice, which precluded det

70 Co-injections of URB597 (0.3 mg/kg daily, i.p.) with cisplatin decreased and delayed the developme

71 ted by an apelin injection (0.1 mumol/kg/day i.p.) during 4 weeks had decreased fat mass, glycemia, a

72 d-type (WT) mice, LY2828360 (3 mg/kg per day i.p. x 12 days) suppressed chemotherapy-induced neuropat

73 Morphine (10 mg/kg per day i.p. x 12 days) tolerance developed in CB2KO mice but no

74 ministration of LY2828360 (0.1 mg/kg per day i.p. x 12 days) with morphine (10 mg/kg per day x 12 day

75 dered tolerant to morphine (10 mg/kg per day i.p. x 12 days), but it was absent in morphine-tolerant

76 tory of LY2828360 treatment (3 mg/kg per day i.p. x 12 days).

77 ing-dose morphine regimen (20-100 mg/kg/day, i.p.).

78 e to cocaine (15 mg kg(-1) day(-1) x 5 days, i.p., 1 or 21 day withdrawal), a presynaptic enhancement

79 TNP-Ficoll delivered i.p. or i.v. induced rapid Ag-specific B-1b cell activat

80 In contrast, when delivered i.p., tumor reduction is accompanied by dose-dependent s

81 on (ocular DTx), but not systemic depletion (i.p. DTx), of betagal-specific iTregs enhanced experimen

82 rotein E-knockout mice fed a high-fat diet), i.p., 0.13 mumol/day NLS peptide administration for 5 we

83 High-dose i.p. MSC administration to newborn mice exposed to 90% O

84 Histologically, high-dose i.p. MSC administration was associated with alveolar sep

85 Intranasal MSC or lower-dose i.p. administration had no significant effects on lung f

86 terial burden and mortality following either i.p. or i.v. inoculation with Y. enterocolitica.

87 n ethanol-induced (1.5 g kg(-1) 20% ethanol, i.p.) conditioned taste aversion (CTA) to saccharin tast

88 Following i.p. LPS injection, autophagy-deficient mice had higher

89 Following i.p. LPS treatment or systemic bacterial challenge, TARM

90 sweetener, SC-45647, was abolished following i.p. injection of AF-353.

91 mpared to macrophages and B cells, following i.p. immunization.

92 Within hours following i.p. FV3 infection, iValpha6 T cells were specifically r

93 shown efficacy against disease that follows i.p. inoculation of bacteria.

94 7-AAG and rapamycin, enabling a platform for i.p. delivery, sustained multi-drug exposure, and potent

95 e by altering the route of immunization from i.p. to s.c.

96 sion was more efficient from i.n.- than from i.p.-challenged gps, with 17% versus 83% of naive gps su

97 Furthermore, i.p. infusion of 5-MTP reduced tumor growth and cancer m

98 rate secondary responses to soluble Ag given i.p. but not to Ag given s.c. in the contralateral footp

99 n combination with paclitaxel (12mg/kg given i.p.), ACT induced a strong increase in therapeutic effi

100 d after the mice had been sensitized to HDM (i.p. injection) and prior to initiation of two intranasa

101 to the draining lymph node in mice immunized i.p. with alum.

102 More importantly, i.p. administration of LPS induced IL-1beta production i

103 endothelial growth factor, and decreases in i.p. numbers of endothelial and myeloid cells, as well a

104 resist terminal prion disease when infected i.p. with mouse-adapted scrapie prions.

105 In contrast to oral infection, i.p. infected CD73(-/-) mice were highly susceptible to

106 were consistent in vivo, because LA injected i.p. into C57BL/6 mice suppressed IL-33-induced plasma c

107 In contrast, ApoE(-/-) mice injected i.p. with Muramyl DiPeptide (MDP) to stimulate NOD2 and

108 now show that Tlr9(-/-) BALB/c mice injected i.p. with TMPD develop more severe autoimmunity than do

109 pancreatitis on PDGs, cerulein was injected i.p., repetitively over 10 weeks, in mice exhibiting obe

110 eically mated C57Bl/6J females were injected i.p. with 50 or 250 mg/kg APAP or phosphate-buffered sal

111 Therefore, C57BL/6 (B6) mice were injected i.p. with VIP, and mRNA, protein, and immunostaining ass

112 antly higher than control mice when injected i.p. with an acetaminophen dose not lethal to the contro

113 nt is actually hypervirulent when inoculated i.p. into C3H/HeN mice.

114 Intraperitoneal (i.p.) injections of alphaS fibrils in hemizygous M83 tra

115 (E3-E22.5) and received an intraperitoneal (i.p.) injection of 1mg/kg LPS at E10.5.

116 y of intravenous (i.v.) and intraperitoneal (i.p.) paclitaxel combined with S-1, "an oral fluoropyrim

117 Surprisingly, chronic intraperitoneal (i.p.) injection of AD animals with either amylin or pram

118 7-13 improved survival from intraperitoneal (i.p.) and intradermal (i.d.) challenge by L. interrogans

119 gonist SCH23390 (10 mug/kg, intraperitoneal (i.p.)).

120 In lean mice, intraperitoneal (i.p.) or intracerebroventricular (i.c.v.) administration

121 ) or water before receiving intraperitoneal (i.p.) doses of ketamine or memantine, or infusions of me

122 cationic adjuvants via the intraperitoneal (i.p.) route has been shown to result in strong CD8(+) T-

123 i cysts systemically by the intraperitoneal (i.p.) route.

124 other FAAH substrates upon intraperitoneal (i.p.) administration to mice, with peak levels achieved

125 ency of intravenous (i.v.), intraperitoneal (i.p.), and intramuscular (i.m.) routes of injection of a

126 n of the peritoneal cavity (intraperitoneal [i.p.] inoculation).

127 aline or midazolam (2mg/kg, intraperitoneal, i.p.), for 14 days beginning 3 days after burn injury.

128 i.v.) and S. aureus given intraperitoneally (i.p.) failed to induce mortality.

129 with a lethal dose of LPS intraperitoneally (i.p.).

130 ed intranasally (i.n.) or intraperitoneally (i.p.) with 10,000 times the 50% lethal dose (LD50) of gp

131 ed intranasally (i.n.) or intraperitoneally (i.p.).

132 MRSA pneumonia, mice were intraperitoneally (i.p.) administered 2 or 4 g/kg of ethanol 30 min prior t

133 Male C57BL/6 mice were intraperitoneally (i.p.) injected with a single dose of APAP (350 mg/kg dis

134 amphotericin B (10 mg/kg intraperitoneally [i.p.] once a day [QD]), or caspofungin (2 mg/kg i.p. QD)

135 Intriguingly, i.p. injections of LIF initiated blastocyst implantation

136 icrog i.c.v.) given before ethanol (1.5 g/kg i.p.) attenuated the sedation and ataxia induced by etha

137 Treatment with inosine (100 mg/kg i.p. at 1, 24 and 48 h following CHI) improved outcome a

138 ansferase-1 inhibitor, oxfenicine (150 mg/kg i.p. daily), resulted in improved whole-body glucose tol

139 6.57% following eight injections of 1 mg/kg i.p. during 39 days, while 3 and 4 showed no such activi

140 iving prolonged treatment with PGB (10 mg/kg i.p. for 21 days), compared with vehicle-treated mice.

141 BNN27 (2,10, and 50 mg/kg i.p. for 7 days) administration 4 weeks post-STZ injecti

142 subsequently administered baclofen (2 mg/kg i.p. or vehicle) immediately after each daily forced ext

143 .] once a day [QD]), or caspofungin (2 mg/kg i.p. QD), and samples were collected on days 7 and 11.

144 lation reward, whereas JJC8-016 (10-30 mg/kg i.p.) did not produce these effects.

145 c administration of R-MOD alone (10-30 mg/kg i.p.) dose-dependently increased locomotor activity and

146 4,6-dicarboxylic acid (LY379268; 0.3-1 mg/kg i.p.) increased the mRNA and protein levels of growth ar

147 atalepsy induced by haloperidol (0.5-5 mg/kg i.p.) or raclopride (2 mg/kg s.c.).

148 ication of baclofen at a high dose (10 mg/kg i.p.) reduced the power of gamma oscillations and the fr

149 re telemetry experiments, SKA-121 (100 mg/kg i.p.) significantly lowered mean arterial blood pressure

150 lar result was observed when BNN27 (10 mg/kg i.p.) was administered at the onset of diabetes, every o

151 anth-9-yl) propanoic acid (LY341495; 1 mg/kg i.p.).

152 se to a challenge dose of morphine (10 mg/kg i.p.).

153 grip strength in mice at doses >/=12.5 mg/kg i.p., and a concentration >/=0.52 muM in water compromis

154 Effects of SzV-1287 (20 mg/kg i.p./day) were investigated in the K/BxN serum-transfer

155 f PHD to intermittent, high doses (50 mug/kg i.p.) of an exogenous erythropoietin receptor agonist in

156 administered at doses of 0.003 to 30 mug/kg i.p., it was able to reduce the infarct volume of mice s

157 PLA2 inhibition using SB-435495 at 10 mg/kg (i.p.) effectively suppressed BRB breakdown in streptozot

158 se of 5 mg/kg i.v.) and MTDs of 60-80 mg/kg (i.p.).

159 morphine (10mg/kg, s.c.), midazolam (2mg/kg, i.p.), and chelerythrine chloride (a non-specific PKC in

160 SB 334867 (10-30mg/kg, i.p.) alone had no effect on ICSS performance or BSR thr

161 Gabapentin (50mg/kg, i.p.) significantly reduced vlPAG neuronal responses to

162 LPS (5mg/kg, i.p.) or saline (0.9% NaCl) was administered to 8-month-

163 induced by glucose administrations (2 g/kg, i.p.) at 0, 1, 3 and 6h post-CCI.

164 found that acute alcohol exposure (2.5 g/kg, i.p.) increased the mRNA expression of Fgf2 in the dorsa

165 ode of hyperglycemia (50% glucose at 2 g/kg, i.p.) initiated immediately after CCI was found to signi

166 Longer alcohol exposure (7 d x 2.5 g/kg, i.p.) restricted these increases to the dorsal striatum,

167 Serum from morphine-treated (1 or 10 mg/kg, i.p. every 12 h) or saline-treated mice was collected at

168 Dihydromyricetin (DHM; 1 mg/kg, i.p. injection), a flavonoid component of herbal medicin

169 A single injection of ketamine (10 mg/kg, i.p.) 24 h prior to testing rescued the CIC stress-induc

170 Ketamine (10 mg/kg, i.p.) administered 2 h, 1 week, or 2 weeks before IS pre

171 orced swim stress or U50,488 (5 or 10 mg/kg, i.p.) administration, significantly potentiated the magn

172 zoline, RS45041, and idazoxan, 3.2-75 mg/kg, i.p.) all occasioned > 80% CR4056-associated lever respo

173 nor a subthreshold cocaine dose (1.25 mg/kg, i.p.) alone were sufficient to reinstate drug-seeking be

174 , rats were injected with cocaine (10 mg/kg, i.p.) and assessed for either locomotor sensitization, m

175 asome blocking agents BAY 11-7082 (30 mg/kg, i.p.) and Brilliant Blue G (BBG) (45.5 mg/kg, i.p.) in a

176 reated (6 once-daily injections of 15 mg/kg, i.p.) and drug-naive rats during a test of cue-evoked in

177 Acute galantamine administration (5.0 mg/kg, i.p.) attenuated nicotine self-administration when anima

178 CBT (6.4 mg/kg, i.p.) attenuated the observed negative emotional consequ

179 d receptor (KOR) antagonist JDTic (30 mg/kg, i.p.) before CSDS reduced stress effects on both sleep a

180 reated with clozapine-N-oxide (CNO; 3 mg/kg, i.p.) before stage II showed blocking when tested in the

181 Systemic injection of kynurenine (100 mg/kg, i.p.) did not affect extracellular tryptophan but produc

182 ine (40 mg/kg, i.p.) or fluoxetine (5 mg/kg, i.p.) for 21 d.

183 with daily injections of cisplatin (1 mg/kg, i.p.) for 7 d, we investigated the anti-hyperalgesic eff

184 WIN55,212-2, dose-dependently (0.5-2 mg/kg, i.p.) impaired short-term plasticity (STP) and long-term

185 We report in rats that PCP (5 mg/kg, i.p.) impairs a well learned, hippocampus-dependent plac

186 .p.) and Brilliant Blue G (BBG) (45.5 mg/kg, i.p.) in a mouse model of CAR-induced pleurisy.

187 e effects of scopolamine (0.1 and 0.5 mg/kg, i.p.) in male rats.

188 pharmacological stressor yohimbine (2 mg/kg, i.p.) induce reinstatement of nicotine CPP in a norbinal

189 , administration of 3alpha-OH-THP (10 mg/kg, i.p.) on the morning of proestrus improved spatial learn

190 systemic administration of 7,8-DHF (5 mg/kg, i.p.) once daily for 10 consecutive days.

191 mine (norBNI) either systemically (10 mg/kg, i.p.) or by local injection in the amygdala (2.5 mug) wi

192 ted daily with either agomelatine (40 mg/kg, i.p.) or fluoxetine (5 mg/kg, i.p.) for 21 d.

193 ce were treated with either Meth (1.2 mg/kg, i.p.) or vehicle in association, dissociation, or absenc

194 U50,488 (5 mg/kg, i.p.) produced anxiety-like behaviors in the elevated-pl

195 ABS-201 (1.5-2.5 mg/kg, i.p.) reduces body and brain temperature by 2-5 degrees

196 ith the A2AR antagonist SCH58261 (0.1 mg/kg, i.p.) reversed the mood and synaptic dysfunction caused

197 1-butanol, and NBI-27914 at doses (30 mg/kg, i.p.) that did not alter nonbinge-like ethanol consumpti

198 nged with lipopolysaccharide (4 or 20 mg/kg, i.p.) to induce endotoxemia with and without recombinant

199 Administration of APAP (300 mg/kg, i.p.) to wild-type mice resulted in the appearance of tw

200 Treatment with ceftriaxone (200 mg/kg, i.p.) upregulated core GLT1 expression and attenuated cu

201 Consistently, cocaine (10 mg/kg, i.p.) was able to induce CPP in Wt but not in NOP (-/-).

202 mg/kg morphine conditioning, CBT (6.4 mg/kg, i.p.) was able to prevent the stress-induced reinstateme

203 Strikingly, URB597 (1 mg/kg, i.p.) was devoid of any deleterious effects in normal co

204 mic administration of propranolol (10 mg/kg, i.p.), a beta-noradrenergic receptor antagonist.

205 rmacological stressor, yohimbine (2.5 mg/kg, i.p.), alone and in combination with cues.

206 er an injection of D-KYN or L-KYN (30 mg/kg, i.p.), newly produced KYNA and 3-HK were recovered from

207 for 1 h, i.v.), pazopanib (30 and100 mg/kg, i.p.), or vandetanib (12.5 and 25 mg/kg, i.p.).

208 inactive metabolite 3beta-OH-THP (10 mg/kg, i.p.), which antagonizes actions of 3alpha-OH-THP.

209 a sub-threshold dose of cocaine (7.5 mg/kg, i.p.).

210 the psychomotor stimulant cocaine (10 mg/kg, i.p.).

211 e after ifenprodil administration (10 mg/kg, i.p.).

212 es and cocaine priming (0, 2.5, 5, 10 mg/kg, i.p.).

213 kg, i.p.), or vandetanib (12.5 and 25 mg/kg, i.p.).

214 in the NAc in response to cocaine (5 mg/kg, i.p.).

215 The CB1R antagonist AM251 (1 or 3 mg/kg, i.p., 30-min pretreatment) administered prior to E2 and

216 en administered repeatedly to rats (6 mg/kg, i.p., four doses), all drugs produce large sustained ele

217 Glu2/3 receptor agonist LY379268 (0.5 mg/kg, i.p., twice daily for 5 days), corrected all the biochem

218 Dexmedetomidine (100 mug/kg, i.p.) prevented and reversed lipopolysaccharide-evoked (

219 versed lipopolysaccharide-evoked (10 mug/kg, i.p.) thermogenesis in free-behaving rats.

220 ry estrogen 17beta-estradiol (E2; 10 mug/kg, i.p., 1-h pretreatment) nor a subthreshold cocaine dose

221 d 12a, 12c, 12e, 12f, and 15b (145 mumol/kg, i.p.) protected 100% of the mice challenged with the sar

222 amidine-oxime (i.e., a dose of 36 mumol/kg, i.p.), 7b and 12e protected 100% of the animals challeng

223 aline or lipopolysaccharide (LPS, 250mug/kg; i.p.), and expression of mRNAs involved in the pathway l

224 st endotoxemia induced by lipopolysaccharide i.p. injection; in these damaged animals, decreased T3 l

225 We immunized mice i.p. with lethally irradiated cells of the colon adenoca

226 CD8(+) T cell (T(CD8+)) ID by injecting mice i.p. with various doses of influenza A virus and assessi

227 Hydrocortisone (0.6 mg/mice i.p.) was administered immediately after hemorrhage.

228 In vivo, mice i.p. injected with miR-133a or miR-146a had marked perit

229 Moreover, SPF WT mice i.p. administered 10 mg/kg MDP were protected against in

230 Pregnant wild type (WT) mice i.p. injected with LPS showed elevated expression of mou

231 In wild-type mice, i.p. injection of AF-353 or simple application of the dr

232 In the mouse model, i.p. administration of 1f, 3f, and 1l derivatives was ef

233 Moreover, i.p. and i.c.v. administrations of SR11935, a brain-pene

234 ound an increased abundance of TAMs in mouse i.p. xenograft models of ovarian cancer that expressed H

235 We used a murine i.p. LPS model of systemic inflammation to mimic sepsis.

236 (45 d) withdrawal from either noncontingent (i.p. injection) or contingent (self-administration) expo

237 motor and ICSS threshold-reducing effects of i.p. injection of mephedrone (5.0 mg/kg), MA (0.5-1.0 mg

238 and BALB/c mice were injected with 10 mug of i.p. TDM in light mineral oil (TDM-IP).

239 re significant surge in serum Abeta than one i.p. injection of the peptide.

240 nfection outcome relative to that of s.c. or i.p. inoculation, including the phenotype of infected ce

241 fected cells following i.d., but not s.c. or i.p., inoculation.

242 jury evoked by intratracheal instillation or i.p. administration of live E. coli or intratracheal ins

243 rCK12a delivered intranasally or i.p. stimulates the expression of CD8alpha, granulysin,

244 (6) cell per pup) were given intranasally or i.p. to newborn severe combined immunodeficiency-beige m

245 Here we show that oral or i.p. tolerization with H. pylori extract prevents the ai

246 ly DC10 treatments, whether transtracheal or i.p., reduced all asthma parameters to near background b

247 ry was later reactivated with either i.v. or i.p. cocaine presentation in the absence of any cue.

248 Garcinol administered after either i.v. or i.p. cocaine reactivation significantly decreased cue-in

249 ompared with mice injected once with i.v. or i.p. TDM.

250 nical studies suggest that intra-peritoneal (i.p.) chemotherapy effectively treats residual EOC after

251 Rat pups received i.p. injection of either saline or Dex (0.25mg/kg) at 24

252 of anaphylaxis in C57BL/6 mice upon repeated i.p. dosing because of an anti-idiotypic anti-drug Ab im

253 vivo, we treated GILZ KO mice with repeated i.p. injections of low-dose LPS followed by treatment wi

254 suitable for efficacy studies, with a single i.p. dose of 10 mg/kg D1(A12) sufficient to maintain IgG

255 Mice that received a single i.p. dose of Pn at the time of infection showed no signs

256 A single i.p. exposure to mannan from Saccharomyces cerevisiae in

257 ear, for metamorphosing axolotls by a single i.p. injection and for axolotl transgenesis using I-SceI

258 We report in this article that a single i.p. injection of 15 mug fatty acid binding protein from

259 A single i.p. injection of either peptide also induces a surge of

260 Therefore, AAV9 was used as a single i.p. injection to deliver LRMIS to test its efficacy in

261 -luc) ovarian cancer xenograft model, single i.p. injections of g-E and g-EAR delayed bioluminescence

262 Th2 responses were also found using standard i.p. OVA sensitization with aluminum hydroxide adjuvant.

263 p.o., and intraperitoneal and subcutaneous (i.p./s.c.) routes.

264 rneal and DLN DCs were depleted by systemic (i.p.) DT treatment.

265 was induced in vivo by carbon tetrachloride i.p. injection or bile duct ligation in wild-type and SE

266 ducing CNS alphaS pathology in M83 mice than i.p. or tail vein injections.

267 Here we demonstrate that i.p. injection of GRP attracts neutrophils in 4 h, and a

268 Previously, we discovered that i.p. injection of a therapeutic vaccine consisting of ba

269 Here, we found that i.p. injection of human cord blood mononuclear cells inf

270 thotopic ID8-T tumor model, we observed that i.p. delivery of a CXCR4 antagonist-expressing OVV led t

271 Here we report that i.p. administration of siRNA encapsulated by glucan shel

272 The i.p. administration of chemotherapy in ovarian and uteri

273 The i.p./i.v. TDM (TDM-IVIP) group was compared with mice in

274 val from leptospiral challenge by either the i.p. or i.d. route.

275 in, further inhibited MM tumor growth in the i.p. model.

276 ammation and bone erosion) is similar in the i.p. versus s.c. immunized mice despite the presence of

277 Administration of OVA+CAF09 via the i.p. route did also result in DC activation, whereas no

278 1, BALB/c mice were sensitized to HDM (three i.p. injections) and administered two intranasal HDM exp

279 Splenectomized mice also fail to respond to i.p. challenge with soluble Ag.

280 d reduced cytokine production in response to i.p. and intravitreal muramyl dipeptide (MDP).

281 ent of peripheral macrophages in response to i.p. injections of LPS or live bacteria, suggesting a po

282 cal type C PS (MCPS)-specific Ig response to i.p.-injected intact, heat-killed Neisseria meningitidis

283 -) cells had a membrane phenotype similar to i.p. connective tissue-type MC, but were smaller and hyp

284 uptake by MPhi also was seen in mice treated i.p. with pristane (develop lupus) but not mineral oil (

285 and miR-223 knockout (KO) mice were treated i.p. with 0.5 mug/g body weight anti-Fas antibody Jo2, a

286 Mice that undergo i.p. sensitization and intratracheal challenge with 10(6

287 the lymphoid organs, which takes place upon i.p. immunization, is required for the subsequent activa

288 We have used i.p. injection of activin type IIB receptor (ActRIIB)-mF

289 and functional effects of intranasal versus i.p. MSC administration in a rodent model of neonatal lu

290 -(13) C6 ]phenylalanine was administered via i.p. injection.

291 Single doses of EtOH (3 g/kg via i.p. injection in rats) produced decreases in surface le

292 Human PMP tissue was i.p. grafted and grown into nude mice, then constituted

293 To confirm the role of ANG2 in sepsis, we i.p. injected LPS into C57BL/6J mice, which rapidly deve

294 Eight weeks of thrice-weekly i.p. injections (0.604 and 6.04 mug/kg of recombinant hu

295 ice with cryptolepine (10 mg/Kg body weight, i.p.) resulted in significant inhibition of tumor growth

296 ithout or with 5-Aza (0.5 mg/kg body weight, i.p.), were used.

297 agent bleomycin (BLM; 0.035 U/g body weight, i.p.).

298 When i.p. injected into mice, the 11SB17 strain causes only s

299 ug exposure, the Pr was higher compared with i.p. injected rats.

300 n MRI showed that curcumin (30mg/kg body wt. i.p. from 12-20 weeks) worsened regional brain atrophy.